Evogene CEO discloses stock option holdings

Evogene Ltd. director and President & CEO Haviv Ofer filed an initial ownership report showing he holds stock options over ordinary shares in the company.

Rhea-AI Filing Summary

Evogene Ltd. director and President & CEO Haviv Ofer filed an initial ownership report showing he holds stock options over ordinary shares in the company. These include options over 22,500 shares at an exercise price of 51.9600 per share expiring on August 8, 2027, 50,000 shares at 10.5000 per share expiring on April 21, 2030, and 52,800 shares at 1.6600 per share expiring on December 23, 2034. A footnote explains that the options granted on December 23, 2024 vest over four years, with 25% vesting after one year and the remaining 75% vesting in equal quarterly installments of 6.25% over the next twelve quarters.

Insider Trade Summary

3 transactions reported

Mixed 3 txns

Insider Haviv Ofer

Role President and CEO

Type	Security	Shares	Price	Value
holding	Stock Option (right to buy ordinary shares)	--	--	--
holding	Stock Option (right to buy ordinary shares)	--	--	--
holding	Stock Option (right to buy ordinary shares)	--	--	--

Holdings After Transaction: Stock Option (right to buy ordinary shares) — 125,300 contracts (Direct)

Footnotes (1)

1. F1. The options reported in this row vest and become exercisable over a period of four years from the December 23, 2024 grant date. 25% of the options vested and became exercisable upon the one-year anniversary of the grant date and the remainder of the options vest and become exercisable equally on a quarterly basis (6.25% per quarter) over the following twelve quarters such that all options will be fully vested and exercisable on the four-year anniversary of the grant date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Evogene (EVGN) CEO Haviv Ofer report on this Form 3?

He reports his initial beneficial ownership in Evogene through stock options. The filing lists three direct option positions over ordinary shares, each with a specific exercise price, expiration date, and underlying share amount, establishing his disclosed equity-based compensation holdings.

How many Evogene ordinary shares are covered by Haviv Ofer’s stock options?

The filing shows separate option positions over 22,500, 50,000, and 52,800 ordinary shares. Each grant is reported individually with its own exercise price and expiration date, outlining the structure of his equity exposure rather than summarizing it into a single total figure.

What are the exercise prices of Haviv Ofer’s Evogene stock options?

He holds stock options with exercise prices of 51.9600, 10.5000, and 1.6600 per ordinary share. Each option series is reported with its own terms, including the number of underlying shares and the respective expiration dates disclosed in the filing.

When do Haviv Ofer’s Evogene stock options expire?

The reported stock options expire on August 8, 2027, April 21, 2030, and December 23, 2034. Each expiration date corresponds to a distinct grant, with its own exercise price and underlying ordinary share amount disclosed as part of his derivative holdings.

How do the December 23, 2024 Evogene options granted to Haviv Ofer vest?

According to the footnote, those options vest over four years from the December 23, 2024 grant date. Twenty-five percent vest after one year, and the remaining options vest in equal quarterly installments of 6.25% over the following twelve quarters until fully vested.

Are Haviv Ofer’s Evogene stock options held directly or indirectly?

The filing characterizes these option positions as directly owned. Each line in the transaction and derivative summaries identifies the ownership type as direct, indicating the options are attributed personally to him rather than to an intermediary entity or related party.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/18/2026 - 08:06 AM Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Haviv Ofer

(Last) (First) (Middle)

13 URI ZVI GRINBERG

(Street)

TEL AVIV 6937919

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
Evogene Ltd. [ EVGN ]

3a. Foreign Trading Symbol
[EVGN]

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy ordinary shares)	08/08/2021	08/08/2027	Ordinary shares	22,500	$51.96	D
Stock Option (right to buy ordinary shares)	04/21/2024	04/21/2030	Ordinary shares	50,000	$10.5	D
Stock Option (right to buy ordinary shares)	(1)	12/23/2034	Ordinary shares	52,800	$1.66	D

Explanation of Responses:

1. The options reported in this row vest and become exercisable over a period of four years from the December 23, 2024 grant date. 25% of the options vested and became exercisable upon the one-year anniversary of the grant date and the remainder of the options vest and become exercisable equally on a quarterly basis (6.25% per quarter) over the following twelve quarters such that all options will be fully vested and exercisable on the four-year anniversary of the grant date.

Remarks:

Exhibit 24.1 - Power of Attorney.

	/s/ Nitsan Deutsch, attorney-in-fact	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)